Anne Prener
Prener most recently served as CEO of Freeline Therapeutics Ltd., a liver-directed gene therapy company, where she scaled the company from preclinical stage company to a fully integrated biotechnology organization. Previously, she was CEO for Gyroscope, a gene therapy company focused on addressing retinal diseases with novel approaches.
- March 2020
Added to: Renovacor Inc. - Philadelphia, PA
Renovacor is a preclinical stage biotechnology company whose mission is to develop improved therapies for genetically derived cardiovascular diseases. The company is currently developing a gene therapy for a rare, familial form of dilated cardiomyopathy. Their lead gene therapy product aims to restore cardiac function in patients with symptomatic heart failure due to a gene mutation.